UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~October 1410, 2011 (~~February~~October 711, 2011)

SENSIVIDA MEDICAL TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

New Jersey	000-07405	22-1937826
(State or other jurisdiction	(Commission	(IRS Employer Identification No.)
of incorporation)	File Number)
Of incorporation)	File Number)
150 Lucius Gordon Drive, Suite 110 West Henrietta, NY		14586
150 Lucius Gordon Drive, Suite 110
West Henrietta, NY		14586
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (585) 413-9080

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)240.14d-2(b))

¨o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1 5.~~01 Entry~~02 ~~into~~Departure aof ~~Material~~Directors ~~Definitive~~or ~~Agreement~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~The registrant~~On ~~("SensiVida")~~October ~~entered~~10, ~~into~~2011 aDavid ~~Placement~~Smith ~~Agent~~resigned ~~Agreement~~from ~~dated September~~the ~~29,~~Board ~~2010~~of ~~with~~Directors ~~J.P.~~of ~~Turner~~the &registrant ~~Company, LLC~~ ("~~JP Turner~~SensiVida") ~~under~~on ~~which JP Turner was appointed exclusive placement agent and financial advisor to SensiVida for a 12 month period from October 1, 2010,~~ the ~~date~~basis of ~~execution of~~ the ~~Placement~~time ~~Agent~~constraints ~~Agreement. Under~~by ~~the~~his ~~Placement~~executive ~~Agent~~and ~~Agreement~~board ~~JP Turner~~position ~~agreed~~with toan ~~use~~emerging ~~its~~growth ~~best~~company ~~efforts~~and tonot ~~sell~~as ~~between $8,000,000 to $10,000,000 of SensiVida's securities, which JP Turner determined would be through~~ a ~~series of~~result ~~tranches involving the sale~~ of ~~Series B convertible preferred stock that are convertible at~~ any ~~time~~disagreement ~~into~~with ~~shares~~SensiVida ofrelating to SensiVida's ~~shares~~operations, ofpolicies ~~common~~or ~~stock~~practices. atOn ~~an exercise~~October ~~price~~10, of2011 $J.35 ~~per~~Montieth ~~share~~Estes and aJohn ~~three~~Spoonhower ~~year~~joined ~~warrant convertible into 50% of SensiVida's shares of common stock into which~~ the ~~Series~~Board ~~B preferred stock is initially convertible (the "Offering"). The Placement Agent Agreement was subject to JP Turner's completion~~ of ~~its~~Directors ~~due diligence investigation~~ of ~~SensiVida~~ ~~to JP Turner's satisfaction, a process that was concluded February 3, 2011~~SensiVida.

~~Under~~From ~~the terms~~1969 ofto ~~the~~1980 ~~Placement~~Mr. ~~Agent~~Estes ~~Agreement,~~was ~~JP Turner will receive (i) cash commissions aggregating 10% of the gross proceeds of the Offering, (ii)~~ a ~~management~~Partner ~~fee~~in ofHarris 3%Beach ofand ~~the~~Wilcox ~~gross proceeds~~ of ~~the Offering~~Rochester, ~~(iii)~~NY. anFrom ~~expense allowance~~2000 ~~fee of 3% of the gross proceeds of the Offering for providing certain services as lead placement agent, (iv) a five-year warrant~~ to ~~purchase~~2005 upMr. toEstes ~~450,000~~was ~~common shares~~Of ~~of SensiVida’s~~Counsel ~~common~~at ~~stock with an exercise price equal to~~ the ~~initial~~law ~~conversion~~firm ~~price~~ of ~~the~~Boylan ~~Series~~Brown BCode ~~Stock~~Vigdor ~~issued~~& inWilson ~~the~~From ~~Offering~~2005 ~~and (v) a five-year warrant~~ to ~~purchase~~2008 ~~that~~Mr. ~~number~~Estes ofwas ~~SensiVida's~~a ~~shares~~partner ofat ~~common stock equal to 16% of~~ the ~~gross~~law ~~proceeds~~firm ~~received by SensiVida through introductions by JP Turner to purchasers~~ of ~~the~~Jaeckle, ~~securities~~Fleischmann ~~divided~~& byMugel ~~the~~LLP. ~~initial~~Since ~~conversion price~~2009 ~~with an exercise price equal to the initial conversion price of the Series B Stock issued in the Offering~~Mr. ~~The~~Estes ~~Company~~has ~~was~~been ~~also~~practicing ~~required~~law toand ~~pay~~assisting atechnology ~~$50,000~~companies ~~nonrefundable~~with ~~fee~~financings toand ~~JP Turner~~licensing ~~as required by the Placement Agent Agreement~~ of ~~which~~their itintellectual ~~has paid $25,000 and will pay the remaining $25,000 after sales commence~~property.

~~The foregoing~~From 1980 to 2000 Mr. Estes held various executive management positions with public and private companies as well as financial services firms. Mr. Estes has served as Vice President and General Counsel for Fourth Dimension Systems Corp.; Chairman and Chief Executive Officer of Optical Imaging Systems, Inc.; and Chief Operating Officer of Scientific Calculations, Inc. Mr. Estes is a ~~summary~~member of the ~~material~~Board ~~terms~~of Directors of ~~the~~Excell ~~Placement~~Partners, ~~Agent~~Inc., ~~Agreement which~~a isseed ~~qualified~~capital fund for companies located in ~~its~~upstate ~~entirety~~New byYork, the ~~Placement~~Upstate ~~Agent~~Venture ~~Agreement~~Association of New York (UVANY), aUNYTECH, ~~copy~~an association of ~~which~~ 11 tech transfer offices of the major research universities in Upstate New York, and the Smart Start Venture Forum of Albany NY. Mr. Estes is ~~attached~~a tomember ~~this~~of ~~Current~~the ~~Report~~Board onof ~~Form~~Directors ~~8-K~~of iCardiac Technologies, Inc., Med Graph Inc., Environmental Energy Technologies, Inc., EET Diesel Systems, Inc., TVT Bio, Inc., and ~~incorporated~~Plures ~~herein~~Technologies, ~~by reference~~Inc.

~~Item 9~~Mr.~~01 Exhibits~~ Estes received his B.ChE. and ~~Financial~~M.ChE. ~~Statements~~degrees from Cornell University and his J.D. degree from the Harvard Law School. SensiVida believes that in light of his executive turnaround experience at several companies and his financing background that Mr. Estes will be a significant addition to the Board and will contribute industry contacts, financing expertise, insights into successfully growing companies, knowledge of stock markets and assistance with positioning SensiVida for commercialization of its medical technology products.

John Spoonhower is currently CTO of the Company. Prior to joining SensiVida, from 2001 to 2008 Mr. Spoonhower was Chief Technologist responsible for technical due diligence for new business Development initiative and Director of External Alliances for Eastman Kodak Company in charge of managing Kodak's multi-million dollar university collaborative research initiatives and corporate venture capital relations. At Kodak, he established several multi-hundred million dollar business enterprises. From July 2008 to August 2009 he was Managing Director of the Kauffman Foundation Innovation interface at Cornell, a multi-university 501(dc) ~~Exhibits~~ (3) non-for-profit designed for corporate sponsors to investigate new business opportunities using teams at both Cornell University and MIT. From July 2008 until joining SensiVida Mr. Spoonhower was President of Opinnovate, Inc., a consulting firm specializing in best practices in open innovation. Mr. Spoonhower has 56 issued patents and has several pending applications before the U.S. Patent and Trademark Office. Mr. Spoonhower received his undergraduate degree from the University of Notre Dame (B.S., Phi Beta Kappa) and his PhD. in Applied and Engineering Physics from Cornell University.

~~10.1 Placement Agent Agreement dated September 29, 2010 between SensiVida Medical Technologies, Inc. and J.P. Turner & Co., LLC~~2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 14, 2011	SensiVida Medical Technologies, Inc.
Date: October 11, 2011	SensiVida Medical Technologies, Inc.
	By:	/s/ Jose Mir
		Jose Mir
		President

Filing Compare · SensiVida Medical Technologies, Inc.